Cantor Fitzgerald Sticks to Their Buy Rating for Sabra Healthcare REIT


Cantor Fitzgerald analyst Joseph France maintained a Buy rating on Sabra Healthcare REIT (NASDAQ: SBRA) today and set a price target of $25. The company’s shares opened today at $19.70.

France noted:

“SBRA reported 1Q18 results that are above our estimates and the FactSet consensus, and it adjusted its 2018 guidance slightly to reflect revised market timing for the redemption of its Series A Preferred Stock and the cancellation of the previously anticipated refinancing of its debt in 2H18.”

According to TipRanks.com, France is a 5-star analyst with an average return of 9.9% and a 56.4% success rate. France covers the Services sector, focusing on stocks such as Cross Country Healthcare, Five Star Quality Care, and US Physical Therapy.

Sabra Healthcare REIT has an analyst consensus of Moderate Buy, with a price target consensus of $21.25.

See today’s analyst top recommended stocks >>

Sabra Healthcare REIT’s market cap is currently $3.47B and has a P/E ratio of 16.23. The company has a Price to Book ratio of 1.01.

Based on the recent corporate insider activity of 74 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sabra Health Care REIT, Inc. operates as a self-administered, self-managed real estate investment trust. The company owns and invests in real estate serving the healthcare industry.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts